HC Wainwright Expects Reduced Earnings for Leap Therapeutics

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Stock analysts at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Leap Therapeutics in a research report issued to clients and investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate of ($0.34). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Leap Therapeutics’ Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.91) EPS and FY2029 earnings at ($0.37) EPS.

Other analysts also recently issued research reports about the stock. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Robert W. Baird downgraded Leap Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $9.00 to $1.25 in a research report on Wednesday, January 29th.

Leap Therapeutics Trading Down 13.2 %

Shares of LPTX opened at $0.32 on Monday. Leap Therapeutics has a 12-month low of $0.31 and a 12-month high of $4.79. The firm has a market capitalization of $12.13 million, a P/E ratio of -0.16 and a beta of 0.35. The firm has a 50-day moving average price of $0.69 and a 200 day moving average price of $2.16.

Leap Therapeutics (NASDAQ:LPTX) last issued its earnings results on Wednesday, March 26th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.02.

Hedge Funds Weigh In On Leap Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Prosperity Wealth Management Inc. acquired a new position in Leap Therapeutics during the fourth quarter worth $63,000. HighTower Advisors LLC purchased a new position in Leap Therapeutics during the 3rd quarter valued at about $65,000. HB Wealth Management LLC grew its position in Leap Therapeutics by 103.2% in the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after acquiring an additional 26,150 shares in the last quarter. Jane Street Group LLC acquired a new position in Leap Therapeutics in the 4th quarter valued at about $107,000. Finally, Key Client Fiduciary Advisors LLC increased its stake in Leap Therapeutics by 12.2% during the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares during the period. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.